We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Changes In Lymphatic Vessels Can Aid Early Identification of Aggressive Oral Cancer

By LabMedica International staff writers
Posted on 23 Feb 2026

Oral cancers are the most common malignant tumors in the head and neck region and cause more than 188,000 deaths worldwide each year. More...

Unlike many other cancers, even small, early-stage oral tumors can be life-threatening. In Finland, up to one in five patients treated at an early stage later die from the disease. Researchers have now identified a biological marker within tumor lymphatic vessels that may help detect high-risk oral cancers at diagnosis.

In a study conducted by researchers at the University of Turku (Turku, Finland), the team analyzed early-stage oral cancer samples from approximately 300 Finnish patients, focusing on defense and structural cells within tumor tissue. By examining multiple protein markers, the researchers identified an unexpected pattern: certain tumors contained an unusually high number of proliferating lymphatic vessels. In healthy oral tissue, lymphatic vessel cells rarely divide and do not typically express proteins linked to cell division.

Tumors with a higher number of proliferating lymphatic vessels were strongly associated with cancer recurrence and mortality. The presence of these dividing lymphatic vessel cells predicted disease progression more accurately than previously established risk factors for oral cancer. The findings, published in Cell Reports Medicine, suggest that assessing these protein markers in lymphatic vessel surface cells could help identify aggressive forms of oral cancer at an early stage.

Early identification of high-risk tumors may allow clinicians to tailor treatment strategies more precisely. Currently, oral cancer treatment primarily involves surgery, and there are limited tools for guiding adjuvant therapy decisions. Researchers believe the newly identified marker could serve as a practical clinical tool and are interested in exploring whether it has similar predictive value in other cancer types.

“We are excited about the results and believe that the findings could also be applied as a practical tool for clinical use,” said the lead author of the study Joni Näsiaho. “Furthermore, it would be interesting to find out whether the marker we discovered has a similar predictive value in other cancer groups.”

Related Links:
University of Turku


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.